Opinion|Videos|March 6, 2025

The PEACE-3 Trial

Panelists discuss how the PEACE-3 trial demonstrated meaningful clinical benefits with the combination of radium-223 and enzalutamide compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), showing both improved radiologic progression-free survival and a significant overall survival advantage of 7.3 months.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Episodes in this series

      Video content above is prompted by the following:

      • The PEACE-3 trial investigated whether the combination of radium-223 and enzalutamide (RAD-ENZ) improves cancer progression over enzalutamide alone in patients with mCRPC.
      • Please discuss the significance of a 31% reduction in radiologic disease progression or death with the combination of RAD-ENZ.
      • Discussing the secondary end point in a bit more detail, the overall survival, from 35 to 42.3 months, was statistically significant. What does this mean in clinical practice?

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!

      Related Content

      Latest CME

      Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee
      Video

      Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

      Nasfat Shehadeh, MD; Jeremie Calais, MD, PhD

      View more
      DSUI Urology on the Beach
      In-Person Event

      DSUI Urology on the Beach

      January 16-18, 2026

      Register now!
      Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
      Video

      Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

      Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

      View more
      Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
      Video

      Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

      Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

      View more
      Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified
      Multimedia

      Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

      Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

      View more
      Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care
      Multimedia

      Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

      Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

      View more
      Radioligand Therapy 101: The Science Behind the Strategy
      Multimedia

      Radioligand Therapy 101: The Science Behind the Strategy

      Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

      View more
      BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer
      Multimedia

      BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

      Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

      View more
      Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
      Multimedia

      Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

      Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

      View more
      Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies
      Video

      Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

      Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

      View more
      Guiding Prostate Cancer Diagnosis with Biomarker Testing
      Multimedia

      Guiding Prostate Cancer Diagnosis with Biomarker Testing

      Aaron D. Berger, MD

      View more
      Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk
      Multimedia

      Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

      Jason M. Hafron, MD

      View more
      Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis
      Multimedia

      Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

      Stacy Loeb, MD, MSc, PhD (Hon)

      View more
      Contact Info

      259 Prospect Plains Rd, Bldg H
      Cranbury, NJ 08512

      609-716-7777

      Brand Logo

      © 2025 MJH Life Sciences®

      All rights reserved.

      Home
      About Us
      News
      Contact Us